How do you approach patients with very low risk stage IIIA cutaneous melanoma for adjuvant immunotherapy?

Very-low-risk stage IIIA disease includes non-ulcerated lesions, primary ≤2 mm thickness, SLN metastasis <1 mm. Per NCCN the toxicity of adjuvant therapy may outweigh the benefit. However, recent studies have shown benefit in stage IIB,IIC with adjuvant pembrolizumab. Can we extrapolate the results to this group?

Community PollStarted

Would you give adjuvant pembrolizumab in low risk IIIA melanoma?

28 physicians have voted

Join Mednetto vote and see how they answered.

1 Answer

Mednet MemberInvited Expert

Medical Oncology · University Hospitals

Answered on · Updated on

Although it may seem that Stage 3A is a higher stage than Stage 2B and 2C, it must be kept in mind that according to AJCC 8 criteria, 2B and 2C melanomas are thicker (with to without ulceration), and a 3A melanoma is by definition a thinner melanoma. A thin melanoma (<2mm) is called a 3A melanoma be...

Join for free or sign in to see the full answer